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becoming a realistic prospect and treatment duration for some therapies has been extended by favorable outcomes, consideration of HRQoL and symptoms is of particular importance.
This review aims to provide an overview of HRQoL in the era of novel therapies in the treatment of advanced melanoma as a means of providing insight for clinical decision making. We will discuss some of the currently available tools used to assess HRQoL in patients with melanoma and examine the recent clinical trials regarding HRQoL outcomes in patients with advanced and metastatic melanoma.
| HRQoL ASSESSMENT TOOLS USED IN CLINICAL TRIAL SETTINGS
The US Centers for Disease Control and Prevention define HRQoL as "an individual's or a group's perceived physical and mental health over time" (Centers for Disease Control and Prevention, 2016) . The majority of recent clinical trials in melanoma that assess HRQoL use the EORTC QLQ-C30 questionnaire (QLQ-C30; Aaronson et al., 1993; Groenvold, Klee, Sprangers, & Aaronson, 1997; Hjermstad, Fossa, Bjordal, & Kaasa, 1995; Kaasa et al., 1995; Osoba et al., 1994; Osoba, Aaronson, Zee, Sprangers, & te Velde, 1997) . The use of the melanoma-specific Functional Assessment of Cancer TherapyMelanoma (FACT-M) questionnaire, first validated in 2008 (Cormier et al., 2008) , has only recently moved into clinical practice.
The QLQ-C30 form is a self-reported, 30-item questionnaire and includes five scales that address patients' level of functioning (physical, role, cognitive, emotional, and social) as well as nine symptom scales or single-item questions (assessing fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties; Aaronson et al., 1993 ; European Organisation for Research and Treatment of Cancer, 2016) . The overall score ranges from 0 to 100 points and has demonstrated consistent responses across populations with various cancers (Aaronson et al., 1993; Hjermstad et al., 1995; Kaasa et al., 1995; Osoba et al., 1994 Osoba et al., , 1997 . In a validation study, a high level of overall agreement was observed between patient answers in the questionnaire and observer interpretations from detailed interviews using the QLQ-C30 questions in an open-ended format (Groenvold et al., 1997) . The QLQ-C30 questionnaire has shown meaningful correlations with Eastern Cooperative Oncology Group (ECOG) performance status and degree of weight loss in patients with lung cancer (Ko et al., 2003) .
Like the QLQ-C30, the Functional Assessment in Cancer Treatment-General (FACT-G) is considered a core questionnaire generalized for all cancers. Its modification, the FACT-M form, is a validated assessment tool that contains an additional block of melanoma-specific questions (Askew et al., 2009; Cormier, Davidson, Xing, Webster, & Cella, 2005; Cormier et al., 2008) . Of 24 melanoma subscale questions, nine items are clearly related to surgical complications (Cormier et al., 2008) . The FACT-M form differs from the QLQ-C30 in the way the items are formulated as statements rather than questions. These statements are emotionally colored and encourage patients to "reflect on their thoughts and feelings throughout" (Luckett et al., 2011) . Another commonly used HRQoL questionnaire is the EuroQol EQ-5D form, which comprises five questions about pain and physical, social, and emotional well-being, as well as a visual analogue scale, which asks the patient to rate his or her health perception on a 0-to-100 scale.
Regardless of the assessment tool used, however, the magnitude of the change in score that is indicative of a clinically significant difference in QoL requires quantification to facilitate clinical interpretations.
In a study that assessed minimally important differences (MIDs) in the QLQ-C30, researchers compared the changes in a given patient's QLQ-C30 score and the same patient's responses to a separate subjective significance questionnaire that used a 7-category scale ranging from "much worse" through "no change" to "much better." The results indicated that a difference of 5-10 points was perceived by the patients as "a little change," 10-20 points as "moderate change," and >20 points as "very much" change in perceptions of patients in physical, emotional, and social functioning (Osoba, Rodrigues, Myles, Zee, & Pater, 1998) . Regarding the FACT-M, MID ranges were between 1 and 9 points depending on the subscale analyzed (Askew et al., 2009) . The MID for the generic EQ-5D instrument (Kind, 1996; Pickard, Neary, & Cella, 2007; Rabin & Charro, 2001 ) was determined to be similar across various cancer types at 0.08. The use of MIDs is highly encour- 
| IMMUNOTHERAPY
Several novel melanoma immunotherapy studies, described in Table 1 and Figure 1 , included the patients' perception of HRQoL in their outcomes Long et al., 2016; Petrella et al., 2015; Revicki et al., 2012; Schadendorf et al., 2016) .
The randomized, double-blind, Phase III MDX010-20 trial compared the efficacy of ipilimumab, gp100 vaccine, and a combination of both agents in patients with previously treated advanced melanoma (Revicki et al., 2012) 
HRQoL Tool

Conclusions
Comments
Monotherapy
MDX010-20
Phase III (Revicki et al., 2012) 676 (0) Ipi + gp100 (9) Phase III (Petrella et al., 2015) 773 (66) Pembro 10 mg/kg Q2W (7); Pembro 10 mg/kg Q3W (10);
Ipi (14) EORTC QLQ-C30 Phase III (Long et al., 2016) 418 (100) Nivo (7); DTIC (12)
Patients in the Nivo arm maintained their global health status longer than patients in DTIC arm Double-blind study in treatment-naive patients; EORTC QLQ-C30 score was a secondary endpoint, and EQ-5D score was an exploratory endpoint
Combination Immunotherapy
CheckMate 069 Phase II Hodi et al., 2016) 142 (100) Nivo + Ipi (55) Phase III 945 (100) Nivo + Ipi (42); Nivo (10); Ipi (16) EORTC QLQ-C30; EuroQol EQ-5D Although patients in the Nivo + Ipi arm had a higher frequency of AEs, no clinically meaningful changes from baseline were observed in any treatment arm
Randomized, double-blind study in treatment-naive patients; EORTC QLQ-C30 was a secondary endpoint, and EQ-5D was an exploratory endpoint. The patients who discontinued treatment prior to the censoring event were not included in QoL analysis AE, adverse event; chemo, chemotherapy; DTIC, dacarbazine; EORTC, European Organisation for Research and Treatment of Cancer; gp100, glycoprotein 100; HRQoL, health-related quality of life; Ipi, ipilimumab; Nivo, nivolumab; Pembro, pembrolizumab; Q2W, every 2 weeks; Q3W, every 3 weeks.
a Included assessments at the time of treatment discontinuation and during subsequent follow-up visits.
Nivolumab was compared with dacarbazine in the random- alone (Hodi et al., 2016; Larkin et al., 2015) . The randomized, doubleblind, Phase II CheckMate 069 trial evaluated a combination of ipilimumab plus nivolumab followed by nivolumab monotherapy versus ipilimumab plus placebo followed by placebo only in patients with previously untreated metastatic melanoma Hodi et al., 2016) , while the much larger randomized, double-blind, Phase III CheckMate 067 trial also included a third arm of nivolumab monotherapy . The latter trial demonstrated a statistically significant but clinically unimportant initial decline of QLQ-C30 global health status in all arms compared to baseline scores (−2.7 for nivolumab, −4.3 for nivolumab + ipilimumab, and −3.1 for ipilimumab at week 5; p ≤ .01). At the same time, no significant deterioration of the global health status was observed in the combination therapy group compared with either monotherapy group.
The EQ-5D utility scores showed normalization of initial decline back to baseline by week 13 in the nivolumab and combination arms; however, in the ipilimumab arm, recovery of EQ-5D scores did not occur until week 19 (after the four cycles of ipilimumab therapy were already completed).
The rate of treatment-related grade 3/4 AEs was increased in patients in the combination group (55%) compared with the monotherapy group (16.3% in the nivolumab group and 27.3% in the ipilimumab group). This observation correlates with the rates of treatment discontinuation due to adverse events in all three arms (for the combination arms of each study, these rates were 55% and 42% for
CheckMate 069 and CheckMate 067, respectively). Notably, patients Prior treatment with IL-2, surgery, or radiotherapy was allowed.
b
Included assessments at the time of disease progression and 4-6 weeks after progression.
who discontinued treatment early were not included in the presented interim QoL analysis.
| BRAF AND MEK INHIBITORS
The introduction of novel BRAF and MEK inhibitors and their combinations has enhanced survival in patients with BRAF V600-mutant metastatic melanoma Chapman et al., 2011; Flaherty et al., 2012; Hauschild et al., 2012; Larkin et al., 2014; Long et al., 2014 Long et al., , 2015 Robert et al., 2015) . HRQoL has been assessed in a number of trials evaluating the efficacy and safety of BRAF inhibitors, MEK inhibitors, or their combination; results have been outlined in Table 2 To date, most studies of HRQoL in patients with advanced or metastatic melanoma have used generic instruments, such as the QLQ-C30 and EQ-5D questionnaires. One validation study revealed potential biases of the questionnaires (Groenvold et al., 1997) .
Examples of these possible biases include selective reporting bias, when patients would not report pain if they believed it did not originate from cancer, and demand characteristics, which posits that cues in the research setting can affect patient responses. The latter phenomenon could be more problematic and pronounced in open-label trials (Orne, 1969) .
Although these generic questionnaires provide a useful overall assessment despite aforementioned caveats, they may not address some specific symptoms associated with new melanoma treatments, such as rash and pruritus, which can substantially impact patients' HRQoL.
Use of the FACT-M instrument may help clinicians focus on HRQoL issues specific to this patient population and overcome some of the limitations of generic assessments. Acknowledging the differences in the two most commonly used HRQoL assessment tools, QLQ-C30 and FACT-M, Luckett et al. (2011) have proposed a useful algorithm for choosing between them, depending upon what aspects of QoL (specific symptoms or emotional state and social support system) a given study focuses on.
Apart from measurement tools, patients' cultural backgrounds can also influence their perception of QoL. For example, Schwarz and Hinz (2001) reported that the QLQ-C30 global health perception score (where a higher score means perception of better health) was slightly higher in randomly selected Norwegian adults compared with Germans, but the scores for constipation and diarrhea were three times higher (where a higher score means more bothersome symptoms) in Norwegians compared with Germans (Hjermstad, Fayers, Bjordal, & Kaasa, 1998) . Such discrepancies might complicate interpretation and clinical application of results from multicenter trials.
| CONCLUSION
Despite the limiting factors discussed herein, we see more wide- Although in some studies, we observed an association between patients' global health perception and the burden of treatment-related adverse events, as a subjective matter, the HRQoL outcomes remain hard to measure. Researchers will need to focus on finding a unified pattern for reporting clinically meaningful HRQoL data.
Providing raw scores from questionnaires and including patients in
HRQoL analysis who discontinued therapy due to toxicity would be important steps in this endeavor.
